title: Elective segmental ureterectomy for transitional cell carcinoma of the ureter: long-term follow-up in a series of 73 patients.
abstract: What's known on the subject? and What does the study add? Upper Urinary Tract (UUT) Transitional Cell Carcinoma (TCC) is an uncommon disease and represents approximately 5% of all urothelial carcinomas. We report our series on 73 patients treated with Kidney Sparing Surgery for UUT TCC. Good results have been achieved in terms of oncological outcome comparing this conservative approach to the radical nephrourectomy.
  
  
  OBJECTIVE
  • To report the long-term oncological outcome in patients with transitional cell carcinoma of the ureter electively treated with kidney-sparing surgery. • To compare our data with the few series reported in the literature.
  
  
  METHODS
  • We considered 73 patients with transitional cell carcinoma of the distal ureter treated in five Italian Departments of Urology. • The following surgeries were carried out: 38 reimplantations on psoas hitch bladder (52%), 21 end-to-end anastomoses (28.8%), 11 direct ureterocystoneostomies (15.1%) and three reimplantations on Boari flap bladder (4.1%). • The median follow-up was 87 months.
  
  
  RESULTS
  • Tumours were pTa in 42.5% of patients, pT1 in 31.5%, pT2 in 17.8% and pT3 in 8.2%. • Recurrence of bladder urothelial carcinoma was found in 10 patients (13.7%) after a median time of 28 months. • The bladder recurrence-free survival at 5 years was 82.2%. • The overall survival at 5 years was 85.3% and the cancer-specific survival rate at 5 years was 94.1%.
  
  
  CONCLUSIONS
  • Our data show that segmental ureterectomy procedures do not result in worse cancer control compared with data in the literature regarding nephroureterectomy.
authors.affiliation: Department of Urology 'L. Giuliani', University of Genoa, Genoa, Italy. alchiede.simonato@unige.it
authors.forename: Alchiede
authors.initials: A
authors.lastname: Simonato
authors.forename: V
authors.initials: V
authors.lastname: Varca
authors.forename: A
authors.initials: A
authors.lastname: Gregori
authors.forename: A
authors.initials: A
authors.lastname: Benelli
authors.forename: M
authors.initials: M
authors.lastname: Ennas
authors.forename: A
authors.initials: A
authors.lastname: Lissiani
authors.forename: M
authors.initials: M
authors.lastname: Gacci
authors.forename: S
authors.initials: S
authors.lastname: De Stefani
authors.forename: M
authors.initials: M
authors.lastname: Rosso
authors.forename: S
authors.initials: S
authors.lastname: Benvenuto
authors.forename: G
authors.initials: G
authors.lastname: Siena
authors.forename: E
authors.initials: E
authors.lastname: Belgrano
authors.forename: F
authors.initials: F
authors.lastname: Gaboardi
authors.forename: M
authors.initials: M
authors.lastname: Carini
authors.forename: G
authors.initials: G
authors.lastname: Bianchi
authors.forename: G
authors.initials: G
authors.lastname: Carmignani
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D002295:Carcinoma, Transitional Cell / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D017558:Elective Surgical Procedures / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D015996:Survival Rate / Q000639:trends; D013997:Time Factors; D016896:Treatment Outcome; D014513:Ureter / Q000473:pathology / Q000601:surgery*; D014516:Ureteral Neoplasms / Q000401:mortality / Q000473:pathology / Q000601:surgery*; D018666:Ureteroscopy / Q000379:methods; D013520:Urologic Surgical Procedures / Q000379:methods*